Base de dados : MEDLINE
Pesquisa : C04.557.465.625.650.240 [Categoria DeCS]
Referências encontradas : 3247 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 325 ir para página                         

  1 / 3247 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29397600
[Au] Autor:Weng Y; Xue SN; Zhang SL; Cheng H; Yan L
[Ad] Endereço:Department of Endocrinology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou 510120, China.
[Ti] Título:[A comparison of clinical characteristics between 2 pedigrees of multiple endocrine neoplasia type 2A with different RET mutations].
[So] Source:Zhonghua Nei Ke Za Zhi;57(2):134-137, 2018 Feb 01.
[Is] ISSN:0578-1426
[Cp] País de publicação:China
[La] Idioma:chi
[Ab] Resumo:Multiple endocrine neoplasia type 2A (MEN2A) is a hereditary syndrome. Here, two different RET proto-oncogen mutation were identified from family members of two MEN2A pedigrees by genetic screening. One RET mutations were found at codons 1893 and 1895 in exon 11 (1893-1895delCGA) from pedigree 1, which is a novel mutation, the other occurs at codon 634 (Cys634Arg) in exon 11 from pedigree 2. However, the clinical characteristics were similar in the patients of the two pedigrees. All the patients were in middle-age at onset. Most of them were firstly diagnosed with bilateral adrenal pheochromocytoma with different degrees of thyroid abnormalities (elevated serum calcitonin with or without thyroid mass, or had been diagnosed with medullary thyroid carcinoma). Some family members were with elevated serum parathyroid hormone but with no other evidences for hyperparathyroidism.
[Mh] Termos MeSH primário: Neoplasias das Glândulas Suprarrenais/diagnóstico
Neoplasia Endócrina Múltipla Tipo 2a/genética
Mutação
Feocromocitoma/diagnóstico
Proteínas Proto-Oncogênicas c-ret/genética
[Mh] Termos MeSH secundário: Neoplasias das Glândulas Suprarrenais/genética
Carcinoma Neuroendócrino/diagnóstico
Carcinoma Neuroendócrino/genética
Éxons
Seres Humanos
Meia-Idade
Neoplasia Endócrina Múltipla Tipo 2a/patologia
Linhagem
Feocromocitoma/genética
Mutação Puntual
Neoplasias da Glândula Tireoide/diagnóstico
Neoplasias da Glândula Tireoide/genética
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE
[Nm] Nome de substância:
EC 2.7.10.1 (Proto-Oncogene Proteins c-ret)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180306
[Lr] Data última revisão:
180306
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180206
[St] Status:MEDLINE
[do] DOI:10.3760/cma.j.issn.0578-1426.2018.02.010


  2 / 3247 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28460476
[Au] Autor:Liu MJ; Liu ZF; Hou YY; Men YM; Zhang YX; Gao LY; Liu H
[Ad] Endereço:Department of Ultrasound, The Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai, Shandong, China.
[Ti] Título:Ultrasonographic characteristics of medullary thyroid carcinoma: a comparison with papillary thyroid carcinoma.
[So] Source:Oncotarget;8(16):27520-27528, 2017 Apr 18.
[Is] ISSN:1949-2553
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:This study was designed to explore differences in the ultrasonographic characteristics of medullary thyroid carcinoma (MTC) and papillary thyroid carcinoma (PTC). This study included 35 cases of MTC and 96 cases of PTC that were surgically and pathologically confirmed. Preoperative ultrasound images were retrospectively reviewed by two physicians (with 5 years' experience in thyroid ultrasound) under the premise of unknown pathological results. Various ultrasonic features of nodules were assessed objectively. The clinical features of components were determined by other physicians. Age, sex, unilateral or bilateral involvement of thyroid gland, lesion size, margin, shape, echogenicity, calcification, intranodular blood flow, cervical lymph node, and tumor node metastasis (TNM) stage were compared between MTC and PTC groups. Age, sex, involvement of the thyroid gland, margin, and calcification were similar for the MTC and PTC groups. Compared with the PTC group, the lesion size in the MTC group was significantly larger (P < 0.001). A taller-than-wide shape (aspect ratio > 1) was significantly less likely in the MTC group than the PTC group (P < 0.001). A mixed echogenicity was significantly more common in the MTC group than the PTC group (P = 0.003). The MTC group had significantly enhanced intranodular blood flow (P < 0.001). The TNM stage of the MTC group was significantly higher than that of PTC group (P = 0.001). Medullary thyroid carcinomas differ significantly from PTCs in lesion size, shape, echogenicity, and intranodular blood flow.
[Mh] Termos MeSH primário: Carcinoma Neuroendócrino/diagnóstico por imagem
Carcinoma Neuroendócrino/patologia
Carcinoma Papilar/diagnóstico por imagem
Carcinoma Papilar/patologia
Neoplasias da Glândula Tireoide/diagnóstico por imagem
Neoplasias da Glândula Tireoide/patologia
Ultrassonografia
[Mh] Termos MeSH secundário: Adulto
Biomarcadores
Carcinoma Neuroendócrino/sangue
Carcinoma Neuroendócrino/cirurgia
Carcinoma Papilar/sangue
Carcinoma Papilar/cirurgia
Feminino
Seres Humanos
Processamento de Imagem Assistida por Computador
Masculino
Meia-Idade
Estadiamento de Neoplasias
Período Pré-Operatório
Neoplasias da Glândula Tireoide/sangue
Neoplasias da Glândula Tireoide/cirurgia
Carga Tumoral
Ultrassonografia/métodos
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Biomarkers)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180305
[Lr] Data última revisão:
180305
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170503
[St] Status:MEDLINE
[do] DOI:10.18632/oncotarget.15897


  3 / 3247 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28460442
[Au] Autor:Bhinge K; Yang L; Terra S; Nasir A; Muppa P; Aubry MC; Yi J; Janaki N; Kovtun IV; Murphy SJ; Halling G; Rahi H; Mansfield A; de Andrade M; Yang P; Vasmatzis G; Peikert T; Kosari F
[Ad] Endereço:Department of Molecular Medicine, Mayo Clinic, Rochester, MN, USA.
[Ti] Título:EGFR mediates activation of RET in lung adenocarcinoma with neuroendocrine differentiation characterized by ASCL1 expression.
[So] Source:Oncotarget;8(16):27155-27165, 2017 Apr 18.
[Is] ISSN:1949-2553
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Achaete-scute homolog 1 (ASCL1) is a neuroendocrine transcription factor specifically expressed in 10-20% of lung adenocarcinomas (AD) with neuroendocrine (NE) differentiation (NED). ASCL1 functions as an upstream regulator of the RET oncogene in AD with high ASCL1 expression (A+AD). RET is a receptor tyrosine kinase with two main human isoforms; RET9 (short) and RET51 (long). We found that elevated expression of RET51 associated mRNA was highly predictive of poor survival in stage-1 A+AD (p=0.0057). Functional studies highlighted the role of RET in promoting invasive properties of A+AD cells. Further, A+AD cells demonstrated close to 10 fold more sensitivity to epidermal growth factor receptor (EGFR) inhibitors, including gefitinib, than AD cells with low ASCL1 expression. Treatment with EGF robustly induced phosphorylation of RET at Tyr-905 in A+AD cells with wild type EGFR. This phosphorylation was blocked by gefitinib and by siRNA-EGFR. Immunoprecipitation experiments found EGFR in a complex with RET in the presence of EGF and suggested that RET51 was the predominant RET isoform in the complex. In the microarray datasets of stage-1 and all stages of A+AD, high levels of EGFR and RET RNA were significantly associated with poor overall survival (p < 0.01 in both analyses). These results implicate EGFR as a key regulator of RET activation in A+AD and suggest that EGFR inhibitors may be therapeutic in patients with A+AD tumors even in the absence of an EGFR or RET mutation.
[Mh] Termos MeSH primário: Adenocarcinoma/genética
Adenocarcinoma/metabolismo
Fatores de Transcrição Hélice-Alça-Hélice Básicos/genética
Carcinoma Neuroendócrino/genética
Carcinoma Neuroendócrino/metabolismo
Regulação Neoplásica da Expressão Gênica
Neoplasias Pulmonares/genética
Neoplasias Pulmonares/metabolismo
Proteínas Proto-Oncogênicas c-ret/genética
Receptor do Fator de Crescimento Epidérmico/metabolismo
[Mh] Termos MeSH secundário: Adenocarcinoma/mortalidade
Adenocarcinoma/patologia
Processamento Alternativo
Carcinoma Neuroendócrino/mortalidade
Carcinoma Neuroendócrino/patologia
Ciclo Celular/genética
Linhagem Celular Tumoral
Movimento Celular/genética
Proliferação Celular
Técnicas de Silenciamento de Genes
Inativação Gênica
Seres Humanos
Neoplasias Pulmonares/mortalidade
Neoplasias Pulmonares/patologia
Gradação de Tumores
Fosforilação
Prognóstico
Ligação Proteica
Inibidores de Proteínas Quinases/farmacologia
RNA Mensageiro/genética
RNA Interferente Pequeno/genética
Receptor do Fator de Crescimento Epidérmico/antagonistas & inibidores
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (ASCL1 protein, human); 0 (Basic Helix-Loop-Helix Transcription Factors); 0 (Protein Kinase Inhibitors); 0 (RNA, Messenger); 0 (RNA, Small Interfering); EC 2.7.10.1 (Proto-Oncogene Proteins c-ret); EC 2.7.10.1 (Receptor, Epidermal Growth Factor)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180305
[Lr] Data última revisão:
180305
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170503
[St] Status:MEDLINE
[do] DOI:10.18632/oncotarget.15676


  4 / 3247 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29390331
[Au] Autor:Tang Q; Zhou Z; Chen J; Di M; Ji J; Yuan W; Liu Z; Wu L; Zhang X; Li K; Shu X
[Ad] Endereço:Department of Gastrointestinal Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
[Ti] Título:Correlation of metastasis characteristics with prognosis in gastric mixed adenoneuroendocrine carcinoma: Two case reports.
[So] Source:Medicine (Baltimore);96(50):e9189, 2017 Dec.
[Is] ISSN:1536-5964
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:RATIONALE: This article is aimed to retrospect the clinicopathological data of 2 cases of gastric MANENCs. MANEC is a rare biphasic tumor type that is coexistence of dual neuroendocrine and adenocarcinoma differentiation with each composing exceeding 30% volume. Gastric MANEC have just been reported anecdotally in the literature due to their rarity and heterogeneity. According to our study, these neoplasms have 3 different metastasis patterns: only adenocarcinomatous or neuroendocrine carcinoma and both of the 2 components. We first focus on the correlation of metastasis characteristics with prognosis in gastric MANEC, which may be potential implications for the choice of chemotherapy. PATIENT CONCERNS: The 2 cases of patient shared several symptoms: epigastric discomfort, weight loss, hematemesis, or melena. DIAGNOSIS: The 2 patients were diagnosis as MANEC based on the identification of histopathological analysis. In case 1, the poor differentiated adenocarcinoma accounted for 30%, the neuroendocrine part account for 70% and both of the 2 components metastasized to the lymph nodes, whereas in case 2, poorly differentiated adenocarcinoma accounted for 70%, the neuroendocrine part for 30% and only the glandular component invaded regional lymph nodes. INTERVENTIONS: The first patient underwent laparoscopic radical gastrectomy and underwent adjuvant chemotherapy, combination of cisplatin, and etoposide successfully. The second patient received radical gastronomy, and did not receive any chemotherapy due to general weakness. OUTCOMES: The first patient is alive with no evidence of recurrence, and the second patient died 6 months after the operation. LESSONS: The assessment of metastatic sites should be a routine pathological practice, which is crucial for clinical decision-making and the selection of management.
[Mh] Termos MeSH primário: Adenocarcinoma/patologia
Carcinoma Neuroendócrino/patologia
Metástase Neoplásica/patologia
Neoplasias Gástricas/patologia
[Mh] Termos MeSH secundário: Adenocarcinoma/cirurgia
Carcinoma Neuroendócrino/cirurgia
Evolução Fatal
Seres Humanos
Masculino
Meia-Idade
Prognóstico
Neoplasias Gástricas/cirurgia
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180301
[Lr] Data última revisão:
180301
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:180203
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000009189


  5 / 3247 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29390301
[Au] Autor:Zhou J; Luo Y; Ma BY; Ling WW; Zhu XL
[Ad] Endereço:Department of Ultrasound.
[Ti] Título:Contrast-enhanced ultrasound diagnosis of hepatic metastasis of concurrent medullary-papillary thyroid carcinoma: A case report.
[So] Source:Medicine (Baltimore);96(50):e9065, 2017 Dec.
[Is] ISSN:1536-5964
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:RATIONALE: Co-occurrence of medullary thyroid carcinoma (MTC) and papillary thyroid carcinoma (PTC) in the same thyroid gland with liver metastasis is a rare condition. To our knowledge, the utility of contrast-enhanced ultrasound (CEUS) to diagnose it is much less. PATIENT CONCERNS: A 33-year-old female was referred to our hospital due to the increase in plasma calcitonin concentration and carcino-embryonic antigen 12 months after her total thyroidectomy. To find metastasis, she received laboratory tests, gray-scale US, and CEUS. In our paper, ethical approval was not necessary, as this article is a case report, which is based on the clinical information of the patient. Because our case does not refer to the patient's privacy, informed consent is not necessary. DIAGNOSES: Gray-scale abdominal ultrasound image demonstrated a mildly hyperechoic nodule in the liver. In CEUS, the nodules were hyperenhanced in the arterial phase. In the late arterial phase, the enhancement was washed out quickly. The nodules presented hypoenhancement in the portal and parenchymal phase, which conformed to the hepatic metastasis. INTERVENTIONS: The patient received thyroid and liver surgery. OUTCOMES: She was free of disease for 10 months at the time of this report. LESSONS: In this case, liver metastases from MTC can be detected and characterized reliably as hypoenhancing lesions during the portal venous and late phases of CEUS, washing out starts early, and is marked. We suspect MTC is a kind of tumor that tends to have rich blood supply and consider contrast-enhanced ultrasound as a suitable method for the follow-up of patients with MTC.
[Mh] Termos MeSH primário: Carcinoma Neuroendócrino/patologia
Carcinoma Papilar/patologia
Neoplasias Hepáticas/diagnóstico por imagem
Neoplasias Hepáticas/secundário
Neoplasias da Glândula Tireoide/patologia
Ultrassonografia/métodos
[Mh] Termos MeSH secundário: Adulto
Carcinoma Neuroendócrino/cirurgia
Carcinoma Papilar/cirurgia
Meios de Contraste
Diagnóstico Diferencial
Feminino
Seres Humanos
Neoplasias Hepáticas/cirurgia
Fosfolipídeos
Hexafluoreto de Enxofre
Neoplasias da Glândula Tireoide/cirurgia
Tireoidectomia
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Contrast Media); 0 (Phospholipids); 0 (contrast agent BR1); WS7LR3I1D6 (Sulfur Hexafluoride)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180301
[Lr] Data última revisão:
180301
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:180203
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000009065


  6 / 3247 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29390266
[Au] Autor:Shi X; Huang C; Xiao F; Liu W; Zeng J; Li X
[Ad] Endereço:Department of Endocrinology and Diabetes.
[Ti] Título:Pycnodysostosis with novel gene mutation and sporadic medullary thyroid carcinoma: A case report.
[So] Source:Medicine (Baltimore);96(50):e8730, 2017 Dec.
[Is] ISSN:1536-5964
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:RATIONALE: Pycnodysostosis is a rare autosomal recessive skeletal dysplasia caused by a mutation in the cathepsin K encoded by cathepsin K gene (CTSK). Medullary thyroid carcinoma (MTC) is also a relatively rare type of primary thyroid carcinoma. PATIENT CONCERNS: A 31-year-old woman presenting a short stature and a palpable nodule in the front of her neck that had gradually increased in size during the last 2 years was referred to our department. She has experienced multiple fractures at lower limbs in the last 2 decades. DIAGNOSES: The patient's clinical examination revealed short stature, underweight, a prominent forehead, stubby fingers, and a fixed nodule in the right thyroid lobe. Intraoral examination revealed multiple clinically malposed and missing teeth, as well as chronic periodontitis with a narrow and grooved palate. Radiographic examination revealed typical widely separated cranial sutures and an open anterior/posterior fontanel with an obtuse gonial angle, acroosteolysis, and osteosclerosis with narrowed medullary cavities. Ultrasonography of the thyroid gland showed a marked hypoechoic solid nodule in the right lobe in which tumor cell clusters were confirmed by ultrasound-guided fine needle aspiration biopsy and was suspected to be MTC. Laboratory tests revealed dramatically elevated serum calcitonin >2000 pg/L (reference range: 0-5 pg/L) and carcinoembryonic antigen (CEA) 134.37 ng/mL (reference range: 0-5 ng/mL). Genotypic screening revealed compound heterozygous mutations in the CTSK gene (c.158delA, P.Asn53Thr/c.C830T, P.Ala277Val) but no mutation associated with the familial forms of MTC. INTERVENTIONS: The patient underwent a total thyroidectomy with right-sided functional neck dissection. OUTCOMES: CEA and serum calcitonin decreased significantly postthyroidectomy, and no further fracture has been reported by the patient so far. LESSONS: The present study is the first to report a rare case of the coexistence of pycnodysostosis with a compound CTSK gene mutation and sporadic MTC. Radiological techniques and gene analysis play key roles in the definitive diagnosis.
[Mh] Termos MeSH primário: Carcinoma Neuroendócrino/complicações
Catepsina K/genética
Mutação
Picnodisostose/genética
Neoplasias da Glândula Tireoide/complicações
[Mh] Termos MeSH secundário: Adulto
Carcinoma Neuroendócrino/cirurgia
Feminino
Seres Humanos
Esvaziamento Cervical
Picnodisostose/complicações
Neoplasias da Glândula Tireoide/cirurgia
Tireoidectomia
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
EC 3.4.22.38 (CTSK protein, human); EC 3.4.22.38 (Cathepsin K)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180301
[Lr] Data última revisão:
180301
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:180203
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000008730


  7 / 3247 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29390263
[Au] Autor:Cai S; Deng H; Chen Y; Wu X; Guan X
[Ad] Endereço:Department of Oncology, The Third Affiliated Hospital of Southern Medical University, Guangzhou, China.
[Ti] Título:Treatment of medullary thyroid carcinoma with apatinib: A case report and literature review.
[So] Source:Medicine (Baltimore);96(50):e8704, 2017 Dec.
[Is] ISSN:1536-5964
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:RATIONALE: Medullary thyroid carcinoma (MTC) is a rare type thyroid carcinoma originating from the thyroid parafollicular cells (C cells). Chemotherapy has a limited efficacy for treating persistent or recurrent MTC. PATIENT CONCERNS: A 46-year-old woman who underwent thyroidectomy for MTC in December 2007. She began experience recurring diarrhea in January 2015 and started to cough and feel shortness of breath in March 2016. DIAGNOSES: A chestcomputed tomography (CT) scan showed metastases in the bilateral lungs, pulmonary hilum, and mediastinal lymph nodes. Percutaneous biopsy of the pulmonary occupying lesions performed on March 21, 2016 indicated medullary carcinoma metastases at the right pulmonary hilum. INTERVENTIONS: This patient was treated with oral apatinib (500 mg daily). OUTCOMES: The patient's symptoms of diarrhea, coughing, and shortness of breath disappeared. CT reexaminations for efficacy assessment at 1, 2, and 3 months after the treatment indicated partial remission. Systemic migrating bone and joint pains occurred during the treatment, which were considered to be adverse events of apatinib. LESSONS: Treatment of MTC with apatinib has been shown to be effective in our case. Tyrosine kinase inhibitors (TKIs) that suppress rearranged during transfection (RET) and vascular endothelial growth factor receptor (VEGFR) should be considered as a effective therapeutic approaches.
[Mh] Termos MeSH primário: Carcinoma Neuroendócrino/tratamento farmacológico
Carcinoma Neuroendócrino/secundário
Neoplasias Pulmonares/tratamento farmacológico
Neoplasias Pulmonares/secundário
Inibidores de Proteínas Quinases/uso terapêutico
Piridinas/uso terapêutico
Neoplasias da Glândula Tireoide/patologia
[Mh] Termos MeSH secundário: Feminino
Seres Humanos
Meia-Idade
Neoplasias da Glândula Tireoide/terapia
Tireoidectomia
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Protein Kinase Inhibitors); 0 (Pyridines); 5S371K6132 (apatinib)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180301
[Lr] Data última revisão:
180301
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:180203
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000008704


  8 / 3247 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29381978
[Au] Autor:Liu W; Chen W; He X; Qu Q; Hong T; Li B
[Ad] Endereço:Department of Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, P. R. China.
[Ti] Título:Cholecystectomy with gallbladder bed cautery might be sufficient for T1bN0M0 neuroendocrine carcinoma of gallbladders: Cases report and literature review.
[So] Source:Medicine (Baltimore);96(47):e8778, 2017 Nov.
[Is] ISSN:1536-5964
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:INTRODUCTION: Neuroendocrine carcinoma was a rare kind tumor in gallbladders. So far, there is no consensus of treatment of the gallbladder neuroendocrine carcinoma. CASE PRESENTATION: Three patients, 1 male and 2 females, were admitted in our hospital because of right upper quadrant pain. No one complained fever, jaundice, weight loss, or carcinoid syndrome-related symptoms such as diarrhea, flushing, edema, and wheezing. The MRI detected the broad base of gallbladder tumors. However, they refused any radical surgery. We performed a laparoscopic cholecystectomy with gallbladder bed cautery. The pathology results showed that 2 cases were mixed neuroendocrine carcinoma (NECs), and 1 case was a simple NEC. Chromogranin A and synaptophysin were positive in all cases. The pathological TNM stages of all patients were in the T1bN0M0 stage. The range of Ki-67 was from 40% to 80%. During the at least 26 months' follow-up, there is no case with the recurrence of the carcinoma without any chemotherapy or radiotherapy. CONCLUSIONS: Cholecystectomy with gallbladder bed cautery might be enough for treatment of T1bN0M0 gallbladder neuroendocrine carcinoma.
[Mh] Termos MeSH primário: Carcinoma Neuroendócrino/cirurgia
Cauterização/métodos
Colecistectomia Laparoscópica/métodos
Neoplasias da Vesícula Biliar/cirurgia
Vesícula Biliar/cirurgia
[Mh] Termos MeSH secundário: Idoso
Carcinoma Neuroendócrino/patologia
Terapia Combinada
Feminino
Neoplasias da Vesícula Biliar/patologia
Seres Humanos
Masculino
Meia-Idade
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE; REVIEW
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180208
[Lr] Data última revisão:
180208
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:180201
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000008778


  9 / 3247 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:29374737
[Au] Autor:Hata M; Koike I; Miyagi E; Asai-Sato M; Kaizu H; Mukai Y; Takano S; Ito E; Sugiura M; Inoue T
[Ad] Endereço:Division of Radiation Oncology, Department of Oncology, Yokohama City University Graduate School of Medicine, Yokohama, Japan mhata@syd.odn.ne.jp.
[Ti] Título:Radiation Therapy for Patients with Bone Metastasis from Uterine Cervical Cancer: Its Role and Optimal Radiation Regimen for Palliative Care.
[So] Source:Anticancer Res;38(2):1033-1040, 2018 02.
[Is] ISSN:1791-7530
[Cp] País de publicação:Greece
[La] Idioma:eng
[Ab] Resumo:AIM: To determine the role of radiation therapy for patients with bone metastasis from uterine cervical cancer and identify an optimal radiation regimen. PATIENTS AND METHODS: A total of 20 patients with bone metastases from uterine cervical cancer received radiation therapy to the pelvis. The median total dose of 60.2 Gy in the 2 Gy per fraction-equivalent dose (EQD2) was delivered to cervical tumors of all patients. Thirteen patients underwent chemotherapy during and/or following radiation therapy. RESULTS: In 18 of 20 patients, the primary tumors disappeared or were markedly reduced after radiation therapy. In all but one of 17 patients with pelvic pain and bleeding, these symptoms disappeared or were remarkably relieved. However, three patients had primary tumor progression at 7, 9, and 15 months after irradiation with total doses of 56.8, 58.4, and 68.3 Gy in EQD2, respectively. Two of these patients had relapses of bleeding and pain. The primary progression-free rate considering all patients was 69% at 1 year and 34% at 2 years. The corresponding overall survival rates were 34% at 1 year, and 8% at 2 years, with an estimated median survival time of 7 months. The number of metastatic bone sites (p=0.027) and administration of chemotherapy (p<0.001) were significant prognostic factors for survival. CONCLUSION: Radiation therapy is effective for relief of pelvic symptoms in patients with bone metastasis from uterine cervical cancer. For patients who are expected to survive for more than 1 year, almost curative-dose irradiation to primary tumors is recommended.
[Mh] Termos MeSH primário: Neoplasias Ósseas/radioterapia
Braquiterapia/normas
Cuidados Paliativos
Neoplasias do Colo do Útero/radioterapia
[Mh] Termos MeSH secundário: Adenocarcinoma/patologia
Adenocarcinoma/radioterapia
Adulto
Idoso
Idoso de 80 Anos ou mais
Neoplasias Ósseas/secundário
Carcinoma Neuroendócrino/patologia
Carcinoma Neuroendócrino/radioterapia
Carcinoma de Células Escamosas/patologia
Carcinoma de Células Escamosas/radioterapia
Estudos de Casos e Controles
Feminino
Seguimentos
Seres Humanos
Masculino
Meia-Idade
Prognóstico
Dosagem Radioterapêutica
Taxa de Sobrevida
Neoplasias do Colo do Útero/patologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180207
[Lr] Data última revisão:
180207
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180129
[St] Status:MEDLINE


  10 / 3247 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28448755
[Au] Autor:Khan MI; Clayman GL; Waguespack SG
[Ti] Título:VISUAL VIGNETTE.
[So] Source:Endocr Pract;23(9):1160, 2017 Sep.
[Is] ISSN:1530-891X
[Cp] País de publicação:United States
[La] Idioma:eng
[Mh] Termos MeSH primário: Carcinoma Neuroendócrino/diagnóstico por imagem
Neoplasias da Glândula Tireoide/diagnóstico por imagem
[Mh] Termos MeSH secundário: Adulto
Feminino
Seres Humanos
Tomografia Computadorizada por Raios X
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1712
[Cu] Atualização por classe:171205
[Lr] Data última revisão:
171205
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170428
[St] Status:MEDLINE
[do] DOI:10.4158/EP171856.VV



página 1 de 325 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde